Arcus Biosciences (NYSE:RCUS) COO Jennifer Jarrett Sells 12,500 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) COO Jennifer Jarrett sold 12,500 shares of Arcus Biosciences stock in a transaction on Monday, October 6th. The stock was sold at an average price of $14.54, for a total transaction of $181,750.00. Following the completion of the transaction, the chief operating officer directly owned 214,232 shares of the company’s stock, valued at approximately $3,114,933.28. This represents a 5.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jennifer Jarrett also recently made the following trade(s):

• On Wednesday, October 8th, Jennifer Jarrett sold 37,792 shares of Arcus Biosciences stock. The shares were sold at an average price of $15.05, for a total transaction of $568,769.60.

Arcus Biosciences Stock Performance

Shares of RCUS opened at $15.05 on Thursday. Arcus Biosciences, Inc. has a 1 year low of $6.50 and a 1 year high of $18.98. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -4.75 and a beta of 0.77. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.50 and a current ratio of 4.50. The firm has a fifty day moving average of $11.32 and a 200-day moving average of $9.58.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.03. Arcus Biosciences had a negative net margin of 109.56% and a negative return on equity of 55.96%. The company had revenue of $160.00 million during the quarter, compared to the consensus estimate of $32.86 million. During the same quarter in the previous year, the company posted ($1.02) earnings per share. The company’s revenue for the quarter was up 310.3% compared to the same quarter last year. As a group, equities analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Institutional Investors Weigh In On Arcus Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its stake in shares of Arcus Biosciences by 59.1% during the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after purchasing an additional 1,021 shares in the last quarter. CWM LLC raised its position in Arcus Biosciences by 233.6% in the second quarter. CWM LLC now owns 5,441 shares of the company’s stock worth $44,000 after acquiring an additional 3,810 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock worth $57,000 after acquiring an additional 1,796 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Arcus Biosciences by 440.3% in the second quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock worth $62,000 after acquiring an additional 6,191 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Arcus Biosciences by 184.2% in the second quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock worth $69,000 after acquiring an additional 5,476 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on RCUS. Wall Street Zen raised shares of Arcus Biosciences from a “strong sell” rating to a “hold” rating in a report on Saturday, August 9th. Wells Fargo & Company reduced their price target on shares of Arcus Biosciences from $26.00 to $25.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Truist Financial restated a “buy” rating and set a $39.00 price objective (up from $32.00) on shares of Arcus Biosciences in a research note on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a research note on Wednesday. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $23.38.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.